EUVIMEDEUVIMED entdecken
Crossref

Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care

Phillip H Kuo, Erasmus Kofi Poku, Dave M Yamauchi, Susan H Cha, Maria L Parayno, Nicole E Chong, Charles B Nguyen, Sandy T Liu, Alexander M Chehrazi-Raffle, Abhishek Tripathi, Benjamin S Gerendash, Kathleen D Burns und 1 weitere

Journal of Nuclear Medicine Technology · 2025

DOI: 10.2967/jnmt.125.270053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, 2025. Verfasst von Phillip H Kuo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, City of Hope National Medical Center, Duarte, California; and phkuo@coh.org. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Molecular Targeted Therapy, Patient Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The widespread success of 177Lu-PSMA-617 for prostate cancer has generated unprecedented volume in theranostics. Prostate-specific membrane antigen-targeted theranostics is possibly the most complex program in nuclear medicine, requiring interpretation of prostate-specific membrane antigen PET according to specific criteria, incorporating laboratory tests, and on-treatment imaging to guide patient management. Adding to the complexity, these patients often have aggressive disease biology, toxicities from multiple failed therapies, and significant comorbidities. This combination of complexity and growing number of patients has created the critical need for efficient integration of theranostics into regular practice. We describe here the key components of our evolving program and protocols that have improved patient care delivery within our health system. At the core of the program is the establishment of a dedicated multidisciplinary team and regular conference to provide a forum to discuss challenging cases and issues. The creation and distribution of guidelines for imaging and laboratory criteria are critical for streamlining care so that cases are properly selected for further discussion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceGlutamate Carboxypeptidase IIMolecular Targeted TherapyPatient CareProstatic NeoplasmsTheranostic NanomedicineHumansMale

Stichwörter der Autor:innen

prostate cancerprotocolsradiopharmaceutical therapytheranostics

Substanzen

Antigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Department of Radiology, City of Hope National Medical Center, Duarte, California; and phkuo@coh.org.
  • Department of Radiology, City of Hope National Medical Center, Duarte, California; and.
  • Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California.

Zitieren

APA

Kuo, P. H., Poku, E. K., Yamauchi, D. M., Cha, S. H., Parayno, M. L., Chong, N. E., Nguyen, C. B., Liu, S. T., Chehrazi-Raffle, A. M., Tripathi, A., Gerendash, B. S., Burns, K. D., & Dorff, T. B. (2025). Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care. Journal of Nuclear Medicine Technology. https://doi.org/10.2967/jnmt.125.270053

Vancouver

Kuo PH, Poku EK, Yamauchi DM, Cha SH, Parayno ML, Chong NE, et al. Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care. Journal of Nuclear Medicine Technology. 2025. doi:10.2967/jnmt.125.270053

BibTeX
@article{Kuo2025,
  author = {Kuo, Phillip H and Poku, Erasmus Kofi and Yamauchi, Dave M and Cha, Susan H and Parayno, Maria L and Chong, Nicole E and Nguyen, Charles B and Liu, Sandy T and Chehrazi-Raffle, Alexander M and Tripathi, Abhishek and Gerendash, Benjamin S and Burns, Kathleen D and Dorff, Tanya B},
  title = {Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care},
  journal = {Journal of Nuclear Medicine Technology},
  year = {2025},
  doi = {10.2967/jnmt.125.270053}
}
Kostenlos starten →